As with the HDs, avelumab enhanced antigen-specific responses in a subset of the cancer patients, with three out of seven patients displaying an increase in CD8+ T cells that produced IFNγ and/or expressed the degranulation marker CD107a. The gene discussed is LAMP1; the disease is cancer.